Blood biomarkers for canine cancer, from human to veterinary oncology
- PMID: 35815441
- PMCID: PMC9796515
- DOI: 10.1111/vco.12848
Blood biomarkers for canine cancer, from human to veterinary oncology
Abstract
In recent decades, interest in circulating tumour biomarkers is increasing both in human and veterinary oncology. An ideal tumour biomarker would allow early diagnosis of neoplasia, identify it specifically, accurately, establish a prognosis and predict its behaviour, especially regarding different therapeutic solutions. It would also allow to monitor its evolution over time and all this in a non-invasive and inexpensive way. Actually, no biomarkers meeting all of these criteria have been identified in veterinary medicine, particularly due to a lack of specificity of the main protein tumour biomarkers studied to date. However, great hope is currently placed in biomarkers grouped under the name of liquid biopsy, which could prove to be effective tools for common clinical use in the near future. This review gives an update on blood cancer biomarkers studied in dogs, such as ions, proteins, nucleic acids and also circulating cells, of which some might become more prominent in the coming years to help improve the management of animal care.
Keywords: biomarker; cancer; liquid biopsy; veterinary.
© 2022 The Authors. Veterinary and Comparative Oncology published by John Wiley & Sons Ltd.
Conflict of interest statement
The authors have no conflict of interest to declare.
Similar articles
-
CDC6: A novel canine tumour biomarker detected in circulating extracellular vesicles.Vet Comp Oncol. 2022 Jun;20(2):381-392. doi: 10.1111/vco.12781. Epub 2021 Nov 17. Vet Comp Oncol. 2022. PMID: 34743398 Free PMC article.
-
Novel Noninvasive Diagnostics.Vet Clin North Am Small Anim Pract. 2019 Sep;49(5):781-791. doi: 10.1016/j.cvsm.2019.05.002. Epub 2019 Jul 4. Vet Clin North Am Small Anim Pract. 2019. PMID: 31280902 Review.
-
Noninvasive Blood-Based Cancer Detection in Veterinary Medicine.Vet Clin North Am Small Anim Pract. 2024 May;54(3):541-558. doi: 10.1016/j.cvsm.2023.12.008. Epub 2024 Jan 9. Vet Clin North Am Small Anim Pract. 2024. PMID: 38195361 Review.
-
Response evaluation criteria for solid tumours in dogs (v1.0): a Veterinary Cooperative Oncology Group (VCOG) consensus document.Vet Comp Oncol. 2015 Sep;13(3):176-83. doi: 10.1111/vco.12032. Epub 2013 Mar 28. Vet Comp Oncol. 2015. PMID: 23534501
-
Prognostic and predictive markers in canine tumours: rationale and relevance. A review.Vet Q. 2005 Jun;27(2):52-64. doi: 10.1080/01652176.2005.9695186. Vet Q. 2005. PMID: 16022341 Review.
Cited by
-
Age at Tumor Diagnosis in 14,636 Canine Cases from the Pathology-Based UNIPI Animal Cancer Registry, Italy: One Size Doesn't Fit All.Vet Sci. 2024 Oct 8;11(10):485. doi: 10.3390/vetsci11100485. Vet Sci. 2024. PMID: 39453077 Free PMC article.
-
DR-70 (fibrinogen-fibrin degradation products) as a prognostic biomarker in dogs with neoplasms.Vet Q. 2024 Dec;44(1):1-10. doi: 10.1080/01652176.2024.2380049. Epub 2024 Jul 19. Vet Q. 2024. PMID: 39028259 Free PMC article.
-
Low-Invasive Biomarkers of Canine Mammary Tumours.Vet Med Sci. 2025 Mar;11(2):e70280. doi: 10.1002/vms3.70280. Vet Med Sci. 2025. PMID: 40095734 Free PMC article. Review.
-
Development of a sensitive disease-screening model using comprehensive circulating microRNA profiles in dogs: A pilot study.Vet Anim Sci. 2024 Nov 26;27:100414. doi: 10.1016/j.vas.2024.100414. eCollection 2025 Mar. Vet Anim Sci. 2024. PMID: 39691815 Free PMC article.
-
Use of thymidine kinase 1 autoantibody, thymidine kinase antigen, extracellular protein kinase A autoantibody, and C-reactive protein for early detection of malignant tumors in dogs.J Vet Intern Med. 2025 Jan-Feb;39(1):e17266. doi: 10.1111/jvim.17266. J Vet Intern Med. 2025. PMID: 39639774 Free PMC article.
References
-
- Febbo PG, Ladanyi M, Aldape KD, et al. NCCN task force report: evaluating the clinical utility of tumor markers in oncology. J Natl Compr Cancer Netw. 2011;9(Suppl 5):S1‐S32. quiz S33. - PubMed
-
- Pan Q, Kleer CG, van Golen KL, et al. Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis. Cancer Res. 2002;62(17):4854‐4859. - PubMed
-
- MacDonald G, Nalvarte I, Smirnova T, et al. Memo is a copper‐dependent redox protein with an essential role in migration and metastasis. Sci Signal. 2014;7(329):ra56. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical